article thumbnail

STAT+: Documents detail how pharmacy giants Walgreens, CVS, and Walmart failed patients in the opioid epidemic

STAT

In 2011, Walgreens executives were under pressure. Amid a growing addiction crisis, and with the country already awash in prescription painkillers, the federal government was demanding accountability from the pharmacy giant for filling thousands of opioid prescriptions written by doctors in suspiciously large quantities.  

article thumbnail

PQA’s Six Objectives to Advance MTM Quality

PQA

Milestones include endorsement of the Completion Rate for Comprehensive Medication Review performance measure in 2011 and development of the foundational Medication Therapy Problem Categories Framework in 2017. The evolution of PQAs continued involvement in medication therapy management (MTM) spans over a decade.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more

STAT

regulators in 2011. The FDA still has to make a decision on whether to officially place semaglutide on the lists. Novo has repeatedly argued that compounded products are risky, stressing that they are not approved by the FDA. Eylea can treat eye diseases like macular degeneration, macular edema, and retinopathy, and was first approved by U.S.

article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Having worked for CROs since graduating, Sophie joined Pfizer in 2011 and has had various roles within the UK and now global groups. She holds a Bachelor’s degree in Biological Sciences and a PhD in Molecular Biochemistry from the University of Reading, UK. He has participated in four interventional studies and nine others.

article thumbnail

New regulatory relief to benefit Europe’s pharma SMEs

European Pharmaceutical Review

This will allow these firms to complete administrative procedures across the Single Market without needing to re-submit documents. The new rules will repeal the 2011 Directive on late payments and will replace it with a Regulation. Boost investments available for SMEs , for example, ensuring that part of the proposed €7.5

article thumbnail

510(k) Modernization 2023

The FDA Law Blog

Lenz, Principal Medical Device Regulation Expert — On September 6, 2023, FDA announced its latest efforts to modernize the 510(k) process, outlining FDA’s latest improvements to strengthen the 510(k) Program and announcing release of three draft guidance documents.

article thumbnail

FDA looks at pulling speedy approvals for three cancer drugs

pharmaphorum

Briefing documents published by the FDA ahead of the meeting suggest that discussion will focus on ongoing trials that may serve as alternative confirmatory studies. A similar trial called Impassion131 of Tecentriq with regular paclitaxel flopped, and even suggested patients treated with paclitaxel alone may have fared better.

FDA 89